Michelle Hamilton

Promote and market Zoladex, injectable biodegradable implant for the treatment of HR+ Breast Cancer; Re-launch, promote, and market Margenza for the treatment of HER2+ Metastatic Breast Cancer; Re-launched, promoted, and marketed Xermelo, First in Class, Orphan medication for the

treatment of Rare Disease, CSD

• YTD 2025: 111% YoY Growth Zoladex; 120% Margenza (newly acquired product)

• Final Results 2024: 102% Xermelo Rx Goal; 106% Zoladex MOT Goal

• Final Results 2023 (new alignment): 97% Xermelo Rx Goal; 97% Zoladex MOT Goal; H2 110% Xermelo and 101% Zoladex

• Final Results 2022: 120% Xermelo Rx Goal; 100% Zoladex MOT Goal

• Final Results 2021: 121% Xermelo Rx Goal; 105% Zoladex MOT Goal; Increased New Patient Enrollments by 200%; Increased New Prescribers by 116%

• TerSera Team Culture Award Recipient Q4 2021 and Q4 2023

• US Oncology Trifecta Award Recipient 2022

• Zoladex Full Throttle SPIFF Award Recipient 2023 and 2024

• Peer Nominated MVP 2022 and 2023

• Data Analysis to Insights Certification 2023

• Appointed Business Analytics Lead 2022, 2023, 2025 – collaborate with corporate leadership to assess data integrity across platforms, align corporate objectives with internal analytics workflow, develop a projection tool to meet

corporate sales goal

• National Analytics Sales Trainer and Corporate Advisor 2023, 2024, 2025 – train/coach new and tenured Field Sales Account Managers (21), Area Sales Directors (2), Sales Data Analysts (4) on all data platforms

• Identified as a Thought-Leader and Contributor by Corporate Executive Leadership and Chosen to collaborate on 7 National Projects

Strategically positioned Optum Specialty Pharmacy as the Premier Oncology Specialty Pharmacy of choice in North Carolina across multiple specialties Medical Oncology, Hematology, Immunology, Dermatology, Gastroenterology, Genitourinary, Gynecology, Radiation, and Transplant. Key Oncology Accounts include Duke Health, HCA Mission Health, UNC/REX Health, ECU Health, Novant Health, Cone Health, WakeMed Health, Cape Fear Valley Health and FirstHealth of the Carolinas

• Accountable for driving $59.8M in Annual Open Market Revenue (Oral, Physician-Administered Injectables, IV); Consistent Multi-Million Dollar Growth Year over Year

o Final Results 2017: 146% to Revenue Goal ($17M Goal) – Ranked #1 in Revenue Growth

o Final Results 2018: 113% to Revenue Goal ($22.4M Goal)

o Final Results 2019: 103% to Revenue Goal ($32M Goal)

o Final Results 2020: 142% Revenue Growth Year over Year ($59.8M Goal)

• Developed strategic collaborative relationships with external partners (Accounts/Health Systems, Manufacturers, In-Office Dispensaries/Pharmacies, HUB Relations) and internal departments (Finance, Sales Operations, Pharmacy Operations, Marketing, Industry/Trade Relations, and Clinical Management) to improve productivity and efficiency processes to drive sales performance and foster team effectiveness across the organization

o Championed and implemented an innovative sales strategy adopted by the organization to provide time to fill metrics and pharmacy accountability

o Piloted the Oncology Pharmacy Select Program with Duke Health to develop a streamlined, exclusive white-glove program with improved outcomes for accounts and patients with annual growth of $3M

o Mentored/Coached 13 Regional Account Managers across therapies

o Mentored/Coached 8 Certified Pharmacy Technicians

o Advisory Board Consultant to Sales and Pharmacy Operations Leadership

• Cross-functionally coordinated the efforts of Providers, Clinical Staff, Payers, Manufacturers, Supply Chain, Pharmacy Operations, HUB Relations, and Financial Support Agencies while advocating on behalf of the Patient with entrusted access to Patient Health Information (PHI); High-touch involvement in every facet of a prescription referral from intake to fulfillment. Executed comprehensive proficiency in all areas below ensuring operational efficiency:

o Personalized and customized service approach to Account

Management

o Benefits Investigation/Prior Authorization/Appeals Process

o Claims/Coding and Reimbursement including Buy & Bill across all Payer types (Medicare A-B-C-D, Medicaid, Commercial, VA/DoD)

o National and Federal Financial Assistance Programs

o Contracted Service Providers/Supply Chain/Inventory/ Distribution

Accountable for performance improvement/optimization of Risk Adjustment Factor (RAF) score and CMS STAR Ratings for the contracted Medicare Advantage Plan entities of UnitedHealthcare, Evercare, Care Improvement Plus, Humana, Aetna, and Coventry. Key Accounts included Duke Health, UNC Health, WakeMed Health, Cape Fear Valley Health, ECU Health, Novant Health, and Wilmington Health

• Responsible for driving the deployment, process implementation, and system utilization of Optum’s prospective quality initiatives to capture gap closure and High Suspect HCC’s

o Exceeded Goal of Process Implementation by 112%

o Exceeded Goal of OPAF System Utilization by 167%

o Exceeded Goal of Net Reject Rate below National Average by 150%

• Developed comprehensive, provider-specific plans to improve process/workflow to obtain desired, shared outcome of C-suite health system executives and the contracted health plans to move the health system from a “No Risk” to a “Shared Risk” Accountable Care Organization (ACO) agreement

o Facilitated education and engagement of identified providers and staff on HCC coding, Risk Adjustment Payment methodology, HEDIS gap closure/STAR rating, best practices, and process improvement

o Analyzed HEDIS data and educated health systems on identified Population Health Management programs to yield improved patient outcomes

Digital pharmacy serving high-risk patients with barriers to care that cause habitual medication non-adherence. Responsible for developing direct to market plan to increase patient enrollment, targeting and educating Healthcare Providers, Discharge Planners, Home Health Agencies, Transitional Care Teams, and other Patient Support groups in and out of the Community Hospital setting; Entrusted access to Patient Health Information (PHI); Comprehensive understanding and fluency in all areas of Claims/Coding and Market Access/ Reimbursement including Buy & Bill across all Payer types (Medicare A-B-C-D, Medicaid, Commercial, VA/DoD)

• Final Results 2013: 205% Patient Enrollment Growth Year over Year

Re-launched, promoted, and marketed Neudexta, First in Class medication for Rare Disease, Pseudobulbar Affect calling on Neurology, Psychiatry, Physiatry, Cardiology, Community and Academic Hospitals, Behavioral/Psychiatric Units, Rehabilitation Centers, Specialty Pharmacy, Long Term Care, Assisted Living Facilities; Provided educational in-services to healthcare providers on clinical data, managed care access and reimbursement

• Acquired an underperforming territory ranked 73 of 76

• Q1: 254% volume growth over baseline goal

• Q3: 146% volume growth Q3 over Q2

• Q4: 135% volume growth Q4 over Q3 with one month remaining, projected 175%

Promoted and marketed Abilify calling on Psychiatry, Neurology, Internal Medicine, Family Medicine, Community and Academic Hospitals; Presented reimbursement guidelines and strategic navigation of the patient access process

• Reversed a negative trend of -0.70% share change to +1.76% share change in just five months achieving a National rank 147 of 344 from 247 of 344

Generated $4.4M in total sales calling on Psychiatry, Neurology, Pediatrics, Community and Academic Hospitals

• Promoted and marketed Risperdal Oral (tablet and Mtab), Launched Risperdal Consta (First in Class Physician-Administered Injectable device), Concerta, Launched Invega, Launched Invega Sustenna (Physician-Administered Injectable device)

• Provided educational support and developed reimbursement strategies for implementation of Buy & Bill products and services to C-suite leadership, providers, and staff